Wednesday 18 October

   Session 1: Clinical Update on HBV Cure
8:30Workshop Opening & HBV update
Workshop Chairs
8:35TAF – The latest update, which questions remain to be answered?
Pietro Lampertico
, MD, PhD
University of Milan, Milan, Italy
8:50Hepatitis B Cure: From Discovery to Regulatory Endpoints in HBV clinical research: A summary of the AASLD/EASL statement
Fabien Zoulim
, MD, PhD
INSERM, Paris, France
9:05Is immunomodulation really needed to cure HBV?
Harry Janssen,
Toronto Center for Liver Disease, Toronto, Canada
9:40Coffee break
   Session 2: New biomarkers: how will they help us?
10:10How to use new virological biomarkers to assess HBV cure: quantitative HBsAg, HBcrAg, HBV-RNA
Florian Bömmel,
University of Leipzig, Leipzig, Germany
10:25To look inside or outside of the liver for evidence of HBV cure?
Georg Lauer,
Massachusetts General Hospital Boston, MA, USA
   Session 3: Latest update on New Treatment modalities - Immunologic response
11:00How does HBV interact with the immune system
Mala Maini
, MD, PhD
University College London, London, United Kingdom
11:15Innate Immunity : TLR, RIG-I, STING and potential others
Adam Gehring
, PhD
University of Toronto, Toronto, Canada
11:30Adaptive Immunity: Therapeutic vaccination, checkpoint inhibition and potential others
Andre Boonstra,
Erasmus Medical Center, Rotterdam, the Netherlands
11:45Panel Discussion
   Session 4: Latest update on New Treatment modalities - Virologic update
13:15Entry inhibition
Stefan Urban, 
Heidelberg University, Heidelberg, Germany
13:25CCC – DNA inhibition
Anuj Gaggar
Gilead Sciences, Foster City, USA
13:35RNA interference
Bill Symonds,
Arbutus, Burnaby, Canada
13:45Capsid inhibition
Angela Lam, 
Janssen, USA
13:55HBV Ribonuclease H
John Tavis
, PhD
Saint Louis University School of Medicine, Saint Louis, MO, USA
14:05Other virological mechanisms
Stephen Locarnini, BSc, PhD, MBBS, FRCP
Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
14:15Round table discussion
15:00Coffee break
   Session 5: From the science to the clinic
15:30Is personalized therapy needed to achieve success?
Marion Peters
University of California San Francisco, San Francisco, CA, USA
15:50Combination therapy how to navigate in a minefield of efficacy and toxicity?
Jordan Feld
, MD
Toronto Centre for Liver Disease, Toronto, Canada
16:10Innovative trial design
Henry Lik Yuen Chan
, MD
Chinese University of Hong Kong, Hong Kong
16:30Round table discussion:
Trial design, treatment endpoints and regulatory approach
Bill Symonds
, PharmD - Arbutus, Canada
Jeffrey Murray, MD, MPH - U.S. Food and Drug Administration, USA
Fabien Zoulim, MD, PhD - INSERM, France
Henry Lik Yuen Chan, MD - Chinese University of Hong Kong, Hong Kong
Marion Peters, MD - University of California San Francisco, USA
Pietro Lampertico, MD, PhD - University of Milan, Italy
17:30Closure of workshop